PMDA drug package insert
リボスチン点鼻液0.025mg112噴霧用
PMDA Prescription drug · 日本新薬株式会社 · package insert May 28, 2020
Key facts
| Brand names | リボスチン点鼻液0.025mg112噴霧用 |
|---|---|
| Nonproprietary names | レボカバスチン塩酸塩 |
| Companies | 製造販売元／日本新薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 局所用選択H1ブロッカー |
| Therapeutic category codes | 871329 |
| YJ codes | 1329708Q1038 |
| Approval numbers | 21900AMX00770000 |
| Package insert edition | 第1版 |
| Package insert date | May 28, 2020 |
| PMDA document key | 530263_1329708Q1038_2 |
| PMDA company code | 530263 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: